Prevention Is the Best Medicine: Updates for Rheumatoid Arthritis and Lupus

Moderator(s)

• LO

  Liam O'Neil, MD, MHS

  University of Manitoba
  Winnipeg, MB, Canada

  Disclosure(s): Fresnius Kabi: Advisor or Review Panel Member (Terminated, March 19, 2025)
• YG

  Yevgeniya Gartshteyn, MD, MS

  Columbia University Medical Center
  Glen Rock, New Jersey, United States

  Disclosure(s): No financial relationships with ineligible companies to disclose

Session Coordinator(s)

• 

  Janet Pope, MD, FRCPC, MPH

  University of Western Ontario
  London, ON, Canada

  Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing); AstraZeneca: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer-Ingelheim: Advisor or Review Panel Member (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Fresenius Kabi: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Horizon: Advisor or Review Panel Member (Ongoing); Janssen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Merck/MSD: Consultant (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sandoz: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sanofi: Consultant (Ongoing); Therakos: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Zura: Consultant (Ongoing)
• MC

  May Choi, MD, FRCPC, MPH

  University of Calgary
  Calgary, Alberta, Canada

  Disclosure(s): AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Celltrion: Consultant (Terminated, January 1, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, January 1, 2024); GlaxoSmithKlein(GSK): Consultant (Terminated, January 2, 2023); Mallickrodt Pharmaceuticals: Consultant (Terminated, January 2, 2023); MitogenDx: Consultant (Ongoing); Organon: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, January 1, 2024); Werfen: Consultant (Ongoing)

This session will discuss shifting the paradigm to the prevention of autoimmune diseases. Speakers will provide an understanding of ongoing studies in the prevention of lupus and rheumatoid arthritis, including updates from the SMILE trial (HCQ in the prevention of systemic lupus erythematosus), and will also demonstrate a need for future trials in prevention studies of autoimmune diseases.

Presentations:

• 2:30 PM – 3:00 PM Central Time

  Identifying Who Is at Risk of Developing SLE and RA
  

  Speaker: Karen Costenbader, MD, MPH – Brigham and Women's Hospital/ Harvard Medical School
• 3:00 PM – 3:30 PM Central Time

  Rheumatoid Arthritis Prevention: From the Mouse to the Human
  

  Speaker: Kevin Deane, MD,PhD – University of Colorado Denver Anschutz Medical Campus
• 3:30 PM – 4:00 PM Central Time

  Can Lupus Be Prevented? Updates from the SMILE Trial
  

  Speaker: David Karp, MD, PhD – UT Southwestern Medical Center